Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period
about
Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitusClinical Effectiveness and Impact on Insulin Therapy Cost After Addition of Dapagliflozin to Patients with Uncontrolled Type 2 Diabetes.SGLT2 inhibitors in the pipeline for the treatment of diabetes mellitus in Japan.Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.Sodium glucose co-transporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.Addition of dipeptidyl peptidase-4 inhibitors to insulin treatment in type 2 diabetes patients: A meta-analysis.Comparison between sodium-glucose cotransporter 2 inhibitors and pioglitazone as additions to insulin therapy in type 2 diabetes patients: A systematic review with an indirect comparison meta-analysis.Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.
P2860
Q37018165-E7603F65-C219-4172-902A-8D6AE7419D71Q37427304-10BD9A23-0C9C-45BD-BB43-F608BE363BFBQ38824557-FC7DCE02-F3CA-4D91-A75F-799EF187FF9CQ40266818-7C62C7F0-CC02-414F-A844-440AC49D3DE7Q40405896-D4BB6B18-C766-45DC-8457-654B81A04305Q40550581-6FA0D194-03D7-4B79-80A5-3D174C8F99B8Q42696994-E9B6DE61-BDFE-4493-82F2-EB1B7997481DQ47764756-335FED08-3AD5-45E8-9BE5-98217CAD72F4Q48160690-05A32CC7-E65D-440B-A584-B29685906737Q51245889-CA10ABD3-76BF-485F-962F-82BF04DD0970
P2860
Efficacy and safety of dapagliflozin in addition to insulin therapy in Japanese patients with type 2 diabetes: Results of the interim analysis of 16-week double-blind treatment period
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of dapagli ...... double-blind treatment period
@en
Efficacy and safety of dapagli ...... double-blind treatment period.
@nl
type
label
Efficacy and safety of dapagli ...... double-blind treatment period
@en
Efficacy and safety of dapagli ...... double-blind treatment period.
@nl
prefLabel
Efficacy and safety of dapagli ...... double-blind treatment period
@en
Efficacy and safety of dapagli ...... double-blind treatment period.
@nl
P2093
P2860
P356
P1476
Efficacy and safety of dapagli ...... double-blind treatment period
@en
P2093
Eiichi Araki
Ella Ekholm
Eva Johnsson
Hyosung Kim
Michiko Asano
Toshitaka Yajima
Yukiko Onishi
P2860
P304
P356
10.1111/JDI.12453
P577
2015-12-07T00:00:00Z